Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Aruba Sohail, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study
Guangtong Deng, Daishi Li, Yuming Sun, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 51
Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Aruba Sohail, Areej Fatima, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 2
Closed Access | Times Cited: 23
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 22
Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis
Yaqi Wang, Huaiya Xie, Luo Wang, et al.
Virology Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study
Minxue Shen, Chenggen Xiao, Yuming Sun, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 18
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 17
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
A. Cha-Silva, M. Gavaghan, Tobias Bergroth, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 3, pp. e246-e257
Open Access | Times Cited: 5
Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA
Caixia Gao, Zhihui Liu, Zhen Zou, et al.
Expert Opinion on Drug Safety (2025), pp. 1-8
Closed Access
Effectiveness of pharmacological treatments for COVID-19 due to SARS-CoV-2: a systematic literature review
Carolina García‐Vidal, Júlia de Oliveira Gonzalez, Carlos Lumbreras, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies
Kathiaja Miranda Souza, G. Carrasco, Robin Rojas-Cortés, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0284006-e0284006
Open Access | Times Cited: 12
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity
Philipp Flury, Julian Breidenbach, Nadine Krüger, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 493-514
Closed Access | Times Cited: 4
Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials
Huzaifa Ahmad Cheema, Uzair Jafar, Abia Shahid, et al.
BMJ Open (2024) Vol. 14, Iss. 4, pp. e074373-e074373
Open Access | Times Cited: 4
Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis
Aruba Sohail, Huzaifa Ahmad Cheema, Maidah Sohail Mithani, et al.
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 10
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis
George N. Okoli, Nicole Askin, Rasheda Rabbani
The Annals of Family Medicine (2024) Vol. 22, Iss. 4, pp. 336-346
Open Access | Times Cited: 3
Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
Huamin Li, Huai‐rong Xiang, Bei He, et al.
Journal of Global Health (2023) Vol. 13
Open Access | Times Cited: 9
Paxlovid
Niraj Niraj, Sonia Mahajan, Ajay Prakash, et al.
Indian Journal of Pharmacology (2022) Vol. 54, Iss. 6, pp. 452-458
Open Access | Times Cited: 15
Antiandrogens for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials
Huzaifa Ahmad Cheema, Aqeeb Ur Rehman, Asmaa Ahmed Elrashedy, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 8
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances
José Luís Piñana, Ariadna Pérez, Pedro Chorão, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 8
Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2)
Isolde Sommer, Dominic Ledinger, Kylie Thaler, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 10, pp. 1377-1385
Open Access | Times Cited: 8
Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
Anhua Wei, Lu Zeng, Lu Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis
Bei Zheng, Qinqin Zhao, Wenjuan Yang, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107096-107096
Open Access | Times Cited: 2
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
Carlos King Ho Wong, Kristy T. K. Lau, GM Leung
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 639-640
Open Access | Times Cited: 6
Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 3, pp. 396-402
Open Access | Times Cited: 1
Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis
Bahman Amani, Behnam Amani
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0298772-e0298772
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top